Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in first-line metastatic triple-negative breast cancer
jRCT2080223227Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Atezolizumab + nab-paclitaxel with Placebo + nab-paclitaxel (2 arms). Primary endpoints: Progression-free survival (intention-to-treat population) and Progression-free survival (PD-L1-positive subgroup). Started Jun 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223227.